What Is a PCAC Meeting? How the FDA Decides Which Peptides Can Be Compounded

Newtropin

INFORMATIONAL

What Is a PCAC Meeting? How the FDA Decides Which Peptides Can Be Compounded

Published May 11, 2026 • Newtropin Editorial Team • Last Updated: May 2026

If you have been following the FDA's recent peptide regulatory updates, you have probably encountered the acronym "PCAC" — the Pharmacy Compounding Advisory Committee. Understanding what a PCAC meeting is and how it determines which peptides can be legally compounded is essential for any patient, practitioner, or pharmacy navigating the evolving FDA landscape. With critical PCAC meetings scheduled for July 23–24, 2026, and additional sessions planned before February 2027, this guide explains exactly how the PCAC process works and why it matters for your peptide therapy access.

What Is the PCAC?

The Pharmacy Compounding Advisory Committee (PCAC) is a federal advisory committee established to provide independent expert recommendations to the FDA on matters related to pharmacy compounding. The committee is composed of physicians, pharmacists, scientists, and public representatives who bring diverse expertise to the evaluation of bulk drug substances for compounding use.

The PCAC's primary role is to advise the FDA on which bulk drug substances should be included on the lists that govern what compounding pharmacies can and cannot use. Specifically, the PCAC evaluates substances nominated for inclusion on the 503A and 503B bulk drug substances lists.

How the 503A Review Process Works

The journey from peptide nomination to legal compounding status follows a structured process. Understanding each step helps patients and practitioners anticipate timelines and outcomes.

Step 1: Nomination

Any interested party — including healthcare providers, pharmacies, patient advocacy groups, and manufacturers — can nominate a bulk drug substance for inclusion on the 503A list. The nomination must include information about the substance's identity, evidence of its medical use, and safety data.

Step 2: FDA Categorization

After receiving nominations, the FDA evaluates the submissions and places each substance into one of three categories:

Step 3: PCAC Review

For substances moving through the evaluation pipeline — particularly those transitioning out of Category 2 as we are seeing in the April 2026 update — the FDA schedules a PCAC meeting. During this meeting:

• FDA staff present their analysis of the substance, including safety data, evidence of medical use, and compounding considerations
• The committee discusses the evidence and raises questions
• Public comments are heard (patients, practitioners, and stakeholders can submit written or oral testimony)
• The committee votes on a recommendation to the FDA

Step 4: FDA Decision

After receiving the PCAC's recommendation, the FDA makes a final determination. The agency is not legally bound by the PCAC's advice, but it carries significant weight. If the FDA decides to add a substance to the 503A list, compounding pharmacies nationwide can legally use it to prepare patient-specific formulations based on valid prescriptions.

Step 5: Implementation

Once the FDA publishes its final decision, compounding pharmacies can begin (or resume) preparing the substance. State boards of pharmacy may have additional requirements, and pharmacies need time to source compliant raw materials and update their protocols.

What Happens at a PCAC Meeting?

PCAC meetings are typically held in public, with advance notice published in the Federal Register. A typical meeting agenda includes:

1. Opening statements and introductions from FDA officials
2. FDA presentations on each substance under review, covering safety, efficacy, chemistry, and compounding considerations
3. Committee discussion where members ask questions, debate the evidence, and share their expert perspectives
4. Open public hearing where registered speakers — including patients who have benefited from the peptide, prescribing physicians, and pharmacy representatives — can share testimony
5. Committee deliberation and voting on specific questions posed by the FDA (e.g., "Does the available evidence support the safety of this substance for compounding under 503A?")

The public comment period is particularly important. Patient testimony about real-world benefits can influence committee members and provide context that clinical data alone may not capture.

Upcoming PCAC Dates

How PCAC Recommendations Become Policy

After the PCAC meeting, the process typically unfolds as follows:

• Meeting minutes and transcripts are published, usually within weeks of the meeting
• The FDA reviews the committee's recommendations alongside its own analysis
• A proposed rule or guidance update may be issued, sometimes with an additional public comment period
• Final rule is published, officially adding (or declining to add) the substance to the 503A list

The timeline from PCAC recommendation to final FDA action can vary. In some cases it takes months; in others it can take a year or more. Patients should plan for a gradual process rather than immediate changes.

Why This Matters for Peptide Patients

The PCAC process is the gatekeeping mechanism for peptide compounding access in the United States. Understanding it empowers you to:

• Anticipate changes in your peptide availability and plan accordingly with your provider
• Participate meaningfully by submitting public comments to PCAC meetings
• Evaluate claims about peptide legality — now you understand the actual process behind the headlines
• Work proactively with your compounding pharmacy to ensure they are prepared to act once decisions are made

Visit our compounding pharmacy reviews for trusted pharmacy options, and explore our BPC-157 guide and other peptide resources to stay informed about the substances currently under PCAC review.

Conclusion: Your Voice Matters in the PCAC Process

The PCAC is more than a bureaucratic committee — it is the forum where the future of peptide therapy access is being decided. With pivotal meetings on July 23–24, 2026, and additional sessions before February 2027, now is the time to understand the process, engage with it, and prepare for the outcomes. Whether you are a patient, a practitioner, or a pharmacy professional, your informed participation strengthens the case for safe, legal peptide compounding access. Stay updated at newtropin.com and subscribe for meeting updates, analysis, and action alerts.

Know the process. Shape the outcome. Get PCAC meeting alerts and peptide regulatory analysis at newtropin.com.

Disclaimer: This content is for informational purposes only and does not constitute legal or medical advice. Regulatory status may change. Always consult a qualified healthcare provider and check current FDA guidance before starting any peptide therapy.

Track Live FDA Peptide Status

Regulatory status changes as PCAC hearings and FDA determinations roll out. Bookmark our Peptide FDA Compounding Status Tracker 2026 for the latest category and PCAC updates on every peptide.